# Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

> **NCT03143712** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG1690

## Key facts

- **NCT ID:** NCT03143712
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2017-06-14
- **Final completion:** 2017-06-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03143712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03143712, "Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03143712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*